NCT02452736View on ClinicalTrials.gov

Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)

PHASE3CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2015

Conditions
Ischemic Heart DiseaseCardiovascular DiseasesArteriosclerosisCoronary Artery Disease
Interventions
DEVICE

Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System

Trial Locations (2)

210006

Nanjing First Hospital, Nanjing

430022

Wuhan Asia Heart Hospital, Wuhan

Sponsors

Lead Sponsor

Medtronic Vascular
All Listed Sponsors
lead

Medtronic Vascular

INDUSTRY